Zainab Tiamiyu

Zainab Tiamiyu

Auto-generated profile, based on publicly available information

Zainab Tiamiyu

Medical College of Georgia 1 Augusta, GA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2025 in Blood Immunology & Cellular Therapy
Verified
Journal Article
Open access
DPDakota B. Poschel
Dakota B. Poschel
ZTZainab Tiamiyu
Zainab Tiamiyu
PRPriscilla Redd
Priscilla Redd
AMAlyssa Merting
Alyssa Merting
NSNatasha Savage
Natasha Savage
KLKebin Liu
Kebin Liu
Autoimmune lymphoproliferative syndrome (ALPS) is a genetic disease of deregulated leukocyte homeostasis caused by FAS gene mutation or loss of Fas function. Despite three decades having passed since its discovery, except for bone marrow stem transplantation, there is currently no effective treatment for ALPS. The recent breakthrough of COVID-19 mRNA vaccine demonstrated the effectiveness of nucleic acid-based therapy for a human disease. We determined that Fas mediates caspase activation-dependent apoptosis of human hematopoietic cells in vitro. In the ALPS mice, loss of Fas function leads to decreased hematopoietic cell spontaneous apoptosis and mass accumulation of lymphocytes. To restore Fas expression and function, we generated lipid nanoparticle-encapsulated Fas-encoding plasmid (LNP-mFas). LNP-mFas therapy decreased the accumulation of CD4−CD8− lymphocytes and increased CD4+ and CD8+ mature T cells in mice, resulting in suppression of ALPS in mice. We therefore determine that LNP-mFas is potentially an effective therapy for ALPS.